Expression profile of optimised SIV vector in the mouse lung at early timepoints post-delivery

Mostra altre versioni (1)

Dettagli Bibliografici
Autori principali:	Pringle, I, Davies, L, Hyde, S, Gill, D
Natura:	Conference item
Pubblicazione:	Elsevier 2018

Documenti analoghi

Expression profile of optimised SIV vector in the mouse lung at early timepoints post-delivery
di: Pringle, I, et al.
Pubblicazione: (2018)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
di: Hyde, S, et al.
Pubblicazione: (2015)

A method for assessing the distribution of eGFP expressing cells in the mouse lung following lentiviral vector transduction
di: Munday, R, et al.
Pubblicazione: (2018)

Optimising non-viral gene delivery in a tumour spheroid model.
di: Mellor, H, et al.
Pubblicazione: (2006)

Influence of CpG-dinucleotide motifs on the duration of gene expression from plasmid, vectors after in vivo lung delivery
di: Gill, DR, et al.
Pubblicazione: (2007)

Topical delivery of NF-kb decoy related oligodeoxynucleotides reduces pro-inflammatory cytokine response associated with cationic lipid: pDNA vector delivery to murine lungs
di: Varathalingam, et al.
Pubblicazione: (2004)

Rapid determination of rSIV.F/HN lentiviral vector titre
di: Conway, CC, et al.
Pubblicazione: (2020)

Large-scale, high-throughput production of rSIV.F/HN vectors
di: Viegas, MFA, et al.
Pubblicazione: (2020)

OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
di: Sumner-Jones, S, et al.
Pubblicazione: (2009)

Safety profile of dextran-spermine gene delivery vector in mouse lungs
di: Yeo, Wendy Wai Yeng, et al.
Pubblicazione: (2014)

1-year mortality in lung cancer in France according to key timepoints of care pathways
di: Axelle Rivière, et al.
Pubblicazione: (2022-11-01)

The development of gene therapy for diseases of the lung.
di: Gill, DR, et al.
Pubblicazione: (2004)

Progress and prospects: the design and production of plasmid vectors.
di: Gill, DR, et al.
Pubblicazione: (2009)

Autoimmune encephalitis: Early and late findings on serial MR imaging and correlation to treatment timepoints
di: Mahmoud Abunada, et al.
Pubblicazione: (2024-06-01)

Incremental intervention effects in studies with dropout and many timepoints#
di: Kim Kwangho, et al.
Pubblicazione: (2021-12-01)

Identification and Characterization of Metastasis‐Initiating Cells in ESCC in a Multi‐Timepoint Pulmonary Metastasis Mouse Model
di: Ching Ngar Wong, et al.
Pubblicazione: (2024-08-01)

Improving the quantification of rSIV.F/HN vectors for cystic fibrosis gene therapy using droplet digital PCR
di: Gamlen, T, et al.
Pubblicazione: (2020)

Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
di: Pringle, I, et al.
Pubblicazione: (2009)

Gene co-expression network analysis provides novel insights into myostatin regulation at three different mouse developmental timepoints.
di: Xuerong Yang, et al.
Pubblicazione: (2015-01-01)

Stability of Blood DNA Methylation Across Two Timepoints in Three Cohorts
di: Mikołaj Danielewski, et al.
Pubblicazione: (2024-11-01)

Key correlates of exclusive breastfeeding at three timepoints: Evidence from Ethiopia
di: Seblewongel Yigletu, et al.
Pubblicazione: (2022-12-01)

Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys
di: Archana V. Boopathy, et al.
Pubblicazione: (2023-11-01)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
di: Alton, E, et al.
Pubblicazione: (2012)

Immunobiological Correlates of SIV Vaccine Vectors and Macaque Tropism
di: Joseph Antony
Pubblicazione: (2019-12-01)

Multi-Timepoint Metabolic Fingerprinting of a Post-Episode Period of Hypoglycemia and Ketoacidosis Among Children With Type 1 Diabetes
di: Beata Małachowska, et al.
Pubblicazione: (2022-06-01)

AGEs and sRAGE Variations at Different Timepoints in Patients with Chronic Kidney Disease
di: Paolo Molinari, et al.
Pubblicazione: (2021-12-01)

Neuropsychological predictors of conversion from mild cognitive impairment to dementia at different timepoints
di: Davide Quaranta, et al.
Pubblicazione: (2023-09-01)

Optimisation of DNA vector activity and delivery for improved vaccination
di: Hettinga, JK
Pubblicazione: (2022)

Assessment of the air-liquid interface culture model as a tool to validate efficacy of a rSIV.F/HN-CFTR vector
di: Sergijenko, A, et al.
Pubblicazione: (2021)

ENaC knockdown in the mouse lung using RNAi
di: Hyde, S, et al.
Pubblicazione: (2007)

Detection of plasmid DNA vectors following gene transfer to the murine airways.
di: Pringle, I, et al.
Pubblicazione: (2005)

Optomising non-viral gene delivery in a tumuor spheroid model
di: Mellor, H, et al.
Pubblicazione: (2006)

Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy.
di: Davies, L, et al.
Pubblicazione: (2014)

CASi: A framework for cross-timepoint analysis of single-cell RNA sequencing data
di: Yizhuo Wang, et al.
Pubblicazione: (2024-05-01)

Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration‐QTc analysis
di: Michael J. Engwall, et al.
Pubblicazione: (2023-03-01)

431. Lung antibody factory for passive immunisation against influenza
di: Tan, T, et al.
Pubblicazione: (2016)

Plasmid Inhalation: Delivery to the Airways
di: Davies, L, et al.
Pubblicazione: (2006)

Towards gene therapy for cystic fibrosis: Biodistribution of GL67A/pGM169 DNA and mRNA following aerosol delivery to the mouse lung
di: Pringle, I, et al.
Pubblicazione: (2008)

Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airway.
di: Sumner-Jones, S, et al.
Pubblicazione: (2007)

Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
di: José M. Martinez-Navio, et al.
Pubblicazione: (2020-03-01)